Shapiro N L, Strocker A M
Division of Head and Neck Surgery, University of California Los Angeles School of Medicine, Los Angeles, California 90095, USA.
Laryngoscope. 2001 Jun;111(6):997-1001. doi: 10.1097/00005537-200106000-00013.
OBJECTIVES/HYPOTHESIS: Epstein-Barr virus-related (EBV-related) lymphoid hyperplasia of the tonsils and adenoids is a precursor to post-transplantation lymphoproliferative disorder (PTLD). The incidence of post-transplantation adenotonsillar hypertrophy, a potential early sign of PTLD or EBV-related lymphoid hyperplasia, is not known. We sought to identify potential risk factors for adenotonsillar hypertrophy manifested as EBV-related hyperplasia and early PTLD in the pediatric solid organ transplant population.
Cross-sectional analysis.
We developed a 65-point questionnaire concerning obstructive sleep disorder and upper respiratory tract infections and an 8-point focused physical examination, to identify prevalence of and risk factors for adenotonsillar hypertrophy in the pediatric transplant population. We evaluated 120 pediatric solid organ transplant recipients by parental questionnaire and focused adenotonsillar physical examination.
Of the 120 patients, 62 had undergone liver transplantation and 58 had undergone kidney transplantation. Overall, the mean questionnaire score was 8.36 (range, 0-40) and the mean physical examination score was 3.86 (range, 1-8). Patients whose EBV serological test result was negative at the time of transplant had higher scores for both the questionnaire (mean score, 10.24) and the physical examination (mean score, 4.56) than those whose EBV serological test result was positive at the time of transplantation (scores of 7.38 and 3.30 for questionnaire and physical examination, respectively). The difference in examination scores was statistically significant (P <.003).
Epstein-Barr virus seronegativity at the time of organ transplantation is a known risk factor for PTLD, with associated risk of developing EBV-related lymphoid hyperplasia. Our results indicate a higher incidence of symptoms and signs consistent with adenotonsillar hypertrophy in the EBV seronegative population. Adenotonsillar hypertrophy may be a precursor to EBV-related lymphoid hyperplasia and PTLD and must be identified in this patient population.
目的/假设:扁桃体和腺样体的爱泼斯坦-巴尔病毒相关(EBV相关)淋巴组织增生是移植后淋巴组织增生性疾病(PTLD)的前驱病变。移植后腺扁桃体肥大作为PTLD或EBV相关淋巴组织增生的潜在早期迹象,其发生率尚不清楚。我们试图确定小儿实体器官移植人群中表现为EBV相关增生和早期PTLD的腺扁桃体肥大的潜在危险因素。
横断面分析。
我们编制了一份关于阻塞性睡眠障碍和上呼吸道感染的65分问卷以及一份8分的重点体格检查,以确定小儿移植人群中腺扁桃体肥大的患病率和危险因素。我们通过家长问卷和重点腺扁桃体体格检查对120名小儿实体器官移植受者进行了评估。
120例患者中,62例行肝移植,58例行肾移植。总体而言,问卷平均得分为8.36(范围0 - 40),体格检查平均得分为3.86(范围1 - 8)。移植时EBV血清学检测结果为阴性的患者,问卷(平均得分10.24)和体格检查(平均得分4.56)得分均高于移植时EBV血清学检测结果为阳性的患者(问卷和体格检查得分分别为7.38和3.30)。检查得分差异具有统计学意义(P <.003)。
器官移植时EBV血清学阴性是PTLD的已知危险因素,伴有发生EBV相关淋巴组织增生的风险。我们的结果表明,EBV血清学阴性人群中与腺扁桃体肥大一致的症状和体征发生率更高。腺扁桃体肥大可能是EBV相关淋巴组织增生和PTLD的前驱病变,必须在该患者群体中予以识别。